Collegium Pharmaceutical, Inc. COLL Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Product revenues, net by Product | ||||||
| Belbuca | $52.65M-11.0% | $59.14M+1.5% | $58.26M+10.8% | $52.6M+1.8% | $51.66M-6.4% | |
| Jornay PM | $38.89M-15.2% | $45.89M+9.8% | $41.8M+28.1% | $32.63M+14.3% | $28.54M-2.5% | |
| Nucynta ER AG | $1.45M— | —— | —— | —— | $0— | |
| Nucynta ER | $18.23M-1.7% | $18.54M-18.7% | $22.81M+14.4% | $19.95M+1.3% | $19.69M+12.3% | |
| Nucynta IR AG | $1.26M— | —— | —— | —— | $0— | |
| Nucynta IR | $26.08M-11.3% | $29.41M-8.1% | $31.99M+20.7% | $26.5M-3.3% | $27.42M+13.2% | |
| Symproic | $4.19M— | —— | $4.03M+8.1% | $3.72M+32.2% | $2.82M-33.8% | |
| Xtampza ER | $50.77M— | —— | —— | —— | $47.64M-0.4% | |
| Finite-Lived Intangible Assets, Net by Product | ||||||
| Belbuca | $56.54M-25.0% | $75.39M-20.0% | $94.24M-16.7% | $113.09M-14.3% | $131.94M-12.5% | |
| Jornay PM | $502.97M-4.0% | $523.93M-3.8% | $544.89M-3.7% | $565.84M-3.6% | $586.8M-3.4% | |
| Symproic | $40.68M-4.3% | $42.5M-4.1% | $44.32M-3.9% | $46.14M-3.8% | $47.96M-3.7% | |
| Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year by Product | ||||||
| Belbuca | $56.54M— | —— | $18.85M-50.0% | $37.69M-33.3% | $56.54M— | |
| Jornay PM | $62.87M— | —— | $20.96M-50.0% | $41.92M-33.3% | $62.87M— | |
| Symproic | $5.46M— | —— | $1.82M-49.9% | $3.64M-33.3% | $5.47M— | |
| Cost, Amortization by Product | ||||||
| Belbuca | $18.85M0.0% | $18.85M0.0% | $18.85M0.0% | $18.85M0.0% | $18.85M0.0% | |
| Jornay PM | $20.96M0.0% | $20.96M0.0% | $20.96M0.0% | $20.96M0.0% | $20.96M0.0% | |
| Symproic | $1.82M— | —— | $1.82M-0.1% | $1.82M0.0% | $1.82M— | |
| Finite-Lived Intangible Asset, Expected Amortization, Year Four by Product | ||||||
| Belbuca | $0— | $0— | —— | —— | —— | |
| Jornay PM | $83.83M0.0% | $83.83M0.0% | $83.83M0.0% | $83.83M0.0% | $83.83M0.0% | |
| Symproic | $7.29M— | —— | $7.29M0.0% | $7.29M0.0% | $7.29M0.0% | |
| Cost by Product | ||||||
| Belbuca | $360M0.0% | $360M0.0% | $360M0.0% | $360M0.0% | $360M0.0% | |
| Jornay PM | $635M0.0% | $635M0.0% | $635M0.0% | $635M0.0% | $635M0.0% | |
| Symproic | $70M0.0% | $70M0.0% | $70M0.0% | $70M0.0% | $70M0.0% | |
| Finite-Lived Intangible Assets, Accumulated Amortization by Product | ||||||
| Belbuca | $303.46M+6.6% | $284.61M+7.1% | $265.76M+7.6% | $246.91M+8.3% | $228.06M+9.0% | |
| Jornay PM | $132.03M+18.9% | $111.07M+23.3% | $90.11M+30.3% | $69.16M+43.5% | $48.2M+76.9% | |
| Symproic | $29.32M+6.6% | $27.5M+7.1% | $25.68M+7.6% | $23.86M+8.3% | $22.04M+9.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Collegium Pharmaceutical, Inc. break its business down?
- Collegium Pharmaceutical, Inc. (COLL) reports product revenues, net by product across 9 parts — Belbuca, Jornay PM, Nucynta ER AG, Nucynta ER and Nucynta IR AG. Each is extracted from the segment footnotes and tracked over time.
- Where does Collegium Pharmaceutical, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Collegium Pharmaceutical, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
